Proactive Disclosure

Disclosure of Travel and Hospitality Expenses

Dr. Brien Benoit, Chairperson and CEO

Travel Expenses - June 2, 2007 to September 1, 2007

Date(s)	Purpose	Total Cost
6/6/2007 to 6/6/2007	Hearing in the matter of Sanofi Aventis and the medicine Penlac	$14.32
6/11/2007 to 6/12/2007	Hearing in the matter of Janssen-Ortho Inc. and the medicine Concerta	$29.64
6/18/2007 to 6/18/2007	Hearing in the matter of Shire Biochem Inc. and the medicine Adderall XR	$19.32
6/19/2007 to 6/19/2007	Meeting in preparation for meeting with the Minister of Health	$10.32
6/27/2007 to 6/27/2007	Hearing in the matter of Teva Neuroscience G.P.-S.E.N.C. and the medicine Copaxone	$16.32
7/17/2007 to 7/17/2007	Meeting with BIOTECanada on the Guideline Review	$4.46
8/13/2007 to 8/13/2007	Hearing in the matter of Teva Neuroscience G.P.-S.E.N.C. and the medicine Copaxone	$4.46
8/22/2007 to 8/22/2007	Meeting with Rx&D and CGPA on the Guideline Review	$4.46
8/23/2007 to 8/23/2007	Hearing in the matter of Celgene Corporation and the medicine Thalomid	$4.46
8/29/2007 to 8/29/2007	Hearing in the matter of Janssen-Ortho Inc. and the medicine Copaxone	$4.46
	Total:	$112.22

Hospitality Expenses - June 2, 2007 to September 1, 2007

There are no hospitality expenses for this period.